Showing results (411-420 of 1,453) with videos related to
Sort By:
Pageof 146
The Journal of Pharmacy and Pharmacology|January 1, 1993
Stability of GR63178A, a novel pentacyclic pyrroloquinone anticancer compound, in aqueous solutions and biological fluidsR C French, J Cummings, M Nicolson, et al.The Journal of Prevention of Alzheimer'S Disease|July 16, 2022
Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's DiseaseS Cohen, J Cummings, S Knox, et al.Biopharmaceutics & Drug Disposition|January 1, 1985
Adriamycin-loaded albumin microspheres: preparation, in vivo distribution and release in the ratN Willmott, J Cummings, J F Stuart, et al.The Journal of Prevention of Alzheimer'S Disease|April 5, 2018
Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task ForceJ Cummings, N Fox, B Vellas, et al.Clinics in Chest Medicine|July 30, 2023
Occupational Contributions to Respiratory Health DisparitiesSheiphali A Gandhi, Amy Heinzerling, Jennifer Flattery, et al.Journal of Chromatography. B, Biomedical Sciences and Applications|October 12, 1999
Development of a gradient elution high-performance liquid chromatography assay with ultraviolet detection for the determination in plasma of the anticancer peptide [Arg6, D-Trp7,9, mePhe8]-substance P (6-11) (antagonist G), its major metabolites and a C-terminal pyrene-labelled conjugateJ Cummings, A J MacLellan, M Mark, et al.Anti-Cancer Drug Design|October 1, 1995
Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugsI Meikle, J Cummings, J S Macpherson, et al.Journal of Chromatography. B, Biomedical Applications|October 11, 1996
Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatographyJ Cummings, I Meikle, J S Macpherson, et al.Biochemical Pharmacology|October 11, 1996
Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistanceJ Cummings, J S Macpherson, I Meikle, et al.The Orthopedic Clinics of North America|March 29, 2000
Shoulder dislocations in patients older than 40 years of ageL R Stayner, J Cummings, J Andersen, et al.Pageof 146